Introduction: Alteplase (Activase(R)) is a recombinant tissue plasminogen activator (tPA) which has been shown to improve outcomes in acute ischemic stroke and has a low adverse effect profile. The complication of orolingual angioedema has been noted, but a cause and effect relationship has n...
阿替普酶; alteplase; Activase; 爱通立; rt-PA; tissue plasminogen activator; recombinant tissue plasminogen activator; Actilyse 药品类别 创新药; 生物; first-in-class 靶点 tissue plasminogen activator (tPA) 作用机制 重组tPA 药品简介 -- 研发机构 Boehringer Ingelheim ;Roche 最高研发阶段 全球...
Alteplaseis a tissueplasminogenactivator (TPA) produced by recombinant technology. Alteplase is aglycoproteinwhich activates the conversion of plasminogen toplasmin. When administered intravenously alteplase remains inactive in the circulationuntil it binds to fibrin, for which it has a high affinity. Activ...
efficacy and economic benefits of recombinant human TNK tissue plasminogen activator (tenecteplase, rhTNK-tPA, TNK) and recombinant tissue plasminogen activator (alteplase, rtPA) in clinical practice. This study aimed to establish a foundation for refining intravenous thrombolytic therapy tailored to various...
alteplase (r-TPA)acute myocardial infarction.The GUSTO trial and an Australian consensus meeting in 1993 led to the recommendation that recombinant tissue plasminogen activator (r-TPA) was the preferred thrombolytic in patients with acute myocardial infarction (AMI) and ST segment elevation under the ...
Cathflo® Activase® (Alteplase) is atissue plasminogen activator(tPA) produced byrecombinant DNA technology. It is a sterile, purifiedglycoproteinof 527amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissuetype plasminogen activator (tPA) obtained from an estab...
tissue plasminogen activator (tPA), alteplase Additional Exclusion Characteristics of Patients With Ischemic Stroke Who Could Be Treated With tPA From 3 to 4.5 Hours From Symptom Onset: Age > 80 years Severe stroke (NIHSS > 25) Taking an oral anticoagulant regardless of INR ...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is the only available evidence-based treatment for acute isc... A Eissa,I Krass,BV Bajorek - 《Journal of Clinical Pharmacy & Therapeutics》 被引量: 74发表: 2012年 Intravenous alteplase for ischaemic st...
The GUSTO trial and an Australian consensus meeting in 1993 led to the recommendation that recombinant tissue plasminogen activator (r-TPA) was the preferred thrombolytic in patients with acute myocardial infarction (AMI) and ST segment elevation under the age of 75, whose infarction was anterior, ...
返回 拼寫 進度 0% 這一輪 0/7 選項 答案 *AMI* within 12 hours, deep vein thrombosis *(DVT)*, pulmonary embolism *(PE)*, occlusive (ischemic) stroke; AMIs are treated pre-hospital, all others conditions are treated in-hospital學生 ...